Biocombinatorial Approaches for Drug Finding

Genome- and proteome-based research is generating a significant increase in the number of available drug targets. Correspondingly there is an increasing need for novel, diverse compounds, particularly based on natural compounds, as screening resource. The purpose of the Ernst Schering Research Found...

Full description

Corporate Author: SpringerLink (Online service)
Other Authors: Wohlleben, W. (Editor), Spellig, T. (Editor), Müller-Tiemann, B. (Editor)
Format: eBook
Language:English
Published: Berlin, Heidelberg Springer Berlin Heidelberg 2005, 2005
Edition:1st ed. 2005
Series:Ernst Schering Foundation Symposium Proceedings
Subjects:
Online Access:
Collection: Springer eBooks 2005- - Collection details see MPG.ReNa
LEADER 02855nmm a2200337 u 4500
001 EB000373293
003 EBX01000000000000000226345
005 00000000000000.0
007 cr|||||||||||||||||||||
008 130626 ||| eng
020 |a 9783540270553 
100 1 |a Wohlleben, W.  |e [editor] 
245 0 0 |a Biocombinatorial Approaches for Drug Finding  |h Elektronische Ressource  |c edited by W. Wohlleben, T. Spellig, B. Müller-Tiemann 
250 |a 1st ed. 2005 
260 |a Berlin, Heidelberg  |b Springer Berlin Heidelberg  |c 2005, 2005 
300 |a XVIII, 284 p  |b online resource 
505 0 |a Mechanisms and Models -- Functional and Structural Basis for Targeted Modification of Non-Ribosomal Peptlde Synthetases -- Prerequisites for Combinatorial Biosynthesis: Evolution of Hybrid NRPS/PKS Gene Clusters -- Engineering Glycosylation in Bioactive Compounds by Combinatorial Biosynthesis -- Glycosyltransferases and Other Tailoring Enzymes as Tools for the Generation of Novel Compounds -- Enzymatic Incorporation of Halogen Atoms into Natural Compounds -- From Glucose to Antibiotics: What Controls the Fluxes? -- Precursor-Directed Biosynthesis for the Generation of Novel Glycopetides -- Tool-Box: Tailoring Enzymes for Bio-Combinatorial Lead Development and as Markers for Genome-Based Natural Product Lead Discovery -- Natural Product Biosynthetic Assembly Lines: Prospects and Challenges for Repr 
653 |a Molecular biology 
653 |a Molecular Medicine 
653 |a Pharmacology 
653 |a Pharmacology/Toxicology 
700 1 |a Spellig, T.  |e [editor] 
700 1 |a Müller-Tiemann, B.  |e [editor] 
710 2 |a SpringerLink (Online service) 
041 0 7 |a eng  |2 ISO 639-2 
989 |b Springer  |a Springer eBooks 2005- 
490 0 |a Ernst Schering Foundation Symposium Proceedings 
856 |u https://doi.org/10.1007/b138552?nosfx=y  |x Verlag  |3 Volltext 
082 0 |a 611.01816 
520 |a Genome- and proteome-based research is generating a significant increase in the number of available drug targets. Correspondingly there is an increasing need for novel, diverse compounds, particularly based on natural compounds, as screening resource. The purpose of the Ernst Schering Research Foundation Workshop 51 was to provide a forum for an open exchange on perspectives and limitations of biocombinatorial synthesis and the significance of this technology for future drug discovery in light of this challenge. Experts from academia and industry provided contributions covering: the significance of natural compounds for state-of-the-art drug discovery; the underlying basic principle for the biosynthesis of highly complex compounds; and the scope and limitations of combinatorial biosynthesis regarding formation, identification, optimisation, isolation and manufacturing of novel biologically active entities